A Phase I Study Of UCN-01 In Combination With Irinotecan In Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER [estrogen receptor]-Negative, PgR [progesterone receptor]-Negative, HER-2 Not Amplified) Recurrent Breast Cancers (Part II).

Trial Profile

A Phase I Study Of UCN-01 In Combination With Irinotecan In Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER [estrogen receptor]-Negative, PgR [progesterone receptor]-Negative, HER-2 Not Amplified) Recurrent Breast Cancers (Part II).

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Irinotecan (Primary) ; UCN 01 (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top